Abstract: The present invention relates to nimbolide analogs useful as anti-cancer agents and preparation thereof. Particularly the present invention relates to nimbolide analogs of general formula I. wherein, ring M is any ring selected from the group consisting of substituted or unsubstituted aryl, heteroaryl, cycloalkyl and heterocyclic; A and B are selected from the group consisting of C, O, N, S and H; R1, R2, R3, R4, R5 and R6 are selected from the group consisting of C1-C6 alkyl, aryl, heteroaryl, C1-C7 cycloalkyl, heteroalkyl, hydrogen, hydroxy, alkoxy, nitro, halogen, amino, alkylamino, aryl amino and cyano; wherein each of these groups may be further substituted with one or more substituents selected from the group consisting of hydrogen, hydroxy, halogen, cyano, alkyl amino, aryl amino, alkoxy, amino, nitro, aldehyde, carboxylic acid and ester.

Abstract: The present invention relates to an enzymatic process for preparation of optically pure enantiomers of homopropargylic alcohol compounds of formula I, which are useful intermediates for the synthesis of Halichondrin B and analogs. wherein, P is H or an alcohol protecting group, n is an integer ranging from 0-12.

Abstract: Sulfonyl hydroxamic acid compounds have the following general formula: Ring A and B are aryl, heteroaryl, cycloalkyl, fused aryl or fused alkyl group, and R1, R2, R3, R4, R5, and R6 are hydrogen, alkoxy, aryloxy, hydroxy, ester, amide, amino, alkyl, aryl, heteroaryl, halogen, hydroxy, alkoxy, aryloxy, nitro, cyano, ester, or aldehyde. The compounds are HDAC inhibitors. Processes can be used for preparation of these indole-based sulfonyl hydroxamic acid derivatives.

Abstract: The present invention relates to nimbolide analogs useful as anti-cancer agents and preparation thereof. Particularly the present invention relates to nimbolide analogs of general formula I. wherein, ring M is any ring selected from the group consisting of substituted or unsubstituted aryl, heteroaryl, cycloalkyl and heterocyclic; A and B are selected from the group consisting of C, O, N, S and H; R1, R2, R3, R4, R5 and R6 are selected from the group consisting of C1-C6 alkyl, aryl, heteroaryl, C1-C7 cycloalkyl, heteroalkyl, hydrogen, hydroxy, alkoxy, nitro, halogen, amino, alkylamino, aryl amino and cyano; wherein each of these groups may be further substituted with one or more substituents selected from the group consisting of hydrogen, hydroxy, halogen, cyano, alkyl amino, aryl amino, alkoxy, amino, nitro, aldehyde, carboxylic acid and ester.

Abstract: The present invention relates to nimbolide analogs useful as anti-cancer agents and preparation thereof. Particularly the present invention relates to nimbolide analogs of general formula I. wherein, ring M is any ring selected from the group consisting of substituted or unsubstituted aryl, heteroaryl, cycloalkyl and heterocyclic; A and B are selected from the group consisting of C, O, N, S and H; R1, R2, R3, R4, R5 and R6 are selected from the group consisting of C1-C6 alkyl, aryl, heteroaryl, C1-C7 cycloalkyl, heteroalkyl, hydrogen, hydroxy, alkoxy, nitro, halogen, amino, alkylamino, aryl amino and cyano; wherein each of these groups may be further substituted with one or more substituents selected from the group consisting of hydrogen, hydroxy, halogen, cyano, alkyl amino, aryl amino, alkoxy, amino, nitro, aldehyde, carboxylic acid and ester.

Abstract: Sulfonyl hydroxamic acid compounds have the following general formula: Ring A and B are aryl, heteroaryl, cycloalkyl, fused aryl or fused alkyl group, and R1, R2, R3, R4, R5, and R6 are hydrogen, alkoxy, aryloxy, hydroxy, ester, amide, amino, alkyl, aryl, heteroaryl, halogen, hydroxy, alkoxy, aryloxy, nitro, cyano, ester, or aldehyde. The compounds are HDAC inhibitors. Processes can be used for preparation of these indole-based sulfonyl hydroxamic acid derivatives.

Abstract: The present invention relates to a process for the preparation of (1-alkylindol-3-ylmethyl) benzoic acid derivatives, in particular Zafirlukast and analogs thereof. Further, this process is based on protection group free and C—H bond activation strategy involving all step catalytic transformation sequence and comprises the following steps: Sonogashira coupling, indole formation by Sp3 C—H activation, reductive hydrogenation and amidation.

Abstract: The present invention relates to a process for the preparation of (1-alkylindo-3-ylmethyl) benzoic acid derivatives, in particular Zafirlukast and analogs thereof. Further, this process is based on protection group free and C—H bond activation strategy involving all step catalytic transformation sequence and comprises the following steps: Sonogashira coupling, indole formation by Sp3 C—H activation, reductive hydrogenation and amidation.

Abstract: The present invention relates to a process for the preparation of racemic nicotine from 3-pyridylaldehyde using a one-pot or step-wise method. The process comprises the following steps: Stetter reaction, reduction-cyclization and methylation.

Abstract: The present invention relates to nimbolide analogs useful as anti-cancer agents and preparation thereof. Particularly the present invention relates to nimbolide analogs of general formula I. wherein, ring M is any ring selected from the group consisting of substituted or unsubstituted aryl, heteroaryl, cycloalkyl and heterocyclic; A and B are selected from the group consisting of C, O, N, S and H; R1, R2, R3, R4, R5 and R6 are selected from the group consisting of C1-C6 alkyl, aryl, heteroaryl, C1-C7 cycloalkyl, heteroalkyl, hydrogen, hydroxy, alkoxy, nitro, halogen, amino, alkylamino, aryl amino and cyano; wherein each of these groups may be further substituted with one or more substituents selected from the group consisting of hydrogen, hydroxy, halogen, cyano, alkyl amino, aryl amino, alkoxy, amino, nitro, aldehyde, carboxylic acid and ester.

Abstract: The present invention relates to a process for the preparation of racemic nicotine from 3-pyridylaldehyde using a one-pot or step-wise method. The process comprises the following steps: Stetter reaction, reduction-cyclisation and methylation.